SCHEMBL3400256

SCHEMBL3400256

O=c1oc2c[c]ccc2cc1-c1ccc2c(c1)OCO2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAPDH P04406 4/20 0.55
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
MAPT P10636 2/20 0.54
HPGD P15428 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 1/20 0.54
GLA P06280 1/20 0.54
KMT2A Q03164 1/20 0.54
MIF P14174 1/20 0.47
ALOX5 P09917 4/20 0.41
PTPRC P08575 1/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
TNKS O95271 1/20 0.40
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
HCAR2 Q8TDS4 2/20 0.39
ESR2 Q92731 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14881536 0.78 MEN1 (0.85) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL3396561 0.76 RAB9A (0.66) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL14882034 0.75 GAPDH (0.65) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL3398092 0.74 GPR35 (0.48) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL15069281 0.72 ALDH1A1 (0.54) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL7192547 0.71 ESR2 (0.36) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL7421312 0.70 KDM4E (0.49) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL15068726 0.69 KDM4E (0.50) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL15069112 0.67 MAPT (0.48) GAPDHKDM4EALDH1A1MAPTHPGD
SCHEMBL1514529 0.67 CA12 (0.54) KDM4EALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121678-B1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-03 EP disclosed
US-20090312364-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2009-12-17 US disclosed
EP-2121678-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2009-11-25 EP disclosed
WO-2008074798-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312364-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC6A2, SLC18A2, SLC18A1 GAPDH 1488/4885KDM4E 1135/4885ALDH1A1 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.